Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Neoplasms 31Neoplasm Metastasis 28Carcinoma 18Colorectal Neoplasms 16Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14NSCLC 14Adenocarcinoma 11Melanoma 10Lung Diseases 10Brain Neoplasms 10Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8Respiratory Tract Neoplasms 7Non-Squamous Non-Small Cell Lung Cancer 7Neoplasms by Site 7Bronchial Neoplasms 7Respiratory Tract Diseases 6Ovarian Neoplasms 6Neoplasms by Histologic Type 6Meningeal Carcinomatosis 6Squamous Cell Carcinoma of Head and Neck 5Solitary Fibrous Tumor, Pleural 5

Interventions

pembrolizumab 6Nivolumab 3Gemcitabine 3Cisplatin 3Carboplatin 3brigimadlin 2Ramucirumab 2Fluorouracil 2Docetaxel 2Cetuximab 2tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1regorafenib 1pertuzumab 1milademetan 1larotrectinib 1futibatinib 1durvalumab 1cemiplimab 1adagrasib 1Trastuzumab 1TAS-116 1Ritonavir 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Omacor 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Pemetrexed × Thoracic × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡